7 of 23 people found the following review helpful:
1.0 out of 5 stars
A Major Hit Piece Taken Directly from the Pages of Karl Rove, September 24, 2007
Apparently, while Corynne McSherry was a law student at Stanford writing this book, she was looking to carry over some sort of unexplained grudge from her graduate days at UCSD. I didn't know her personally when I was also a graduate student at UCSD, but McSherry was friends with a small subset of students in my laboratory who, instead of doing science, seemed to spend a majority of their days sitting around thinking of ways to try to torment me on the sole basis that I was a highly talented, passionate female scientist. It didn't work most of the time, but still, what a pain in the choo-choo that was!
Anyway, it might go a long way toward explaining why this book reads so much to me like McSherry took a page from the Karl Rove Book of Slime and created this hit piece disguised as an academic work. In fact, it wouldn't surprise me if Agouron Pharmaceuticals, the other half of the "Pelletier v Agouron Pharmaceuticals" lawsuit that is so prominently featured on the opening pages of this book, paid her way through law school in exchange for allowing them to hijack what may have started out as a reasonable thesis (mostly the middle part of the book covering the history of intellectual property in academia), but ended up being some sort of convoluted, sick argument in support of pharmaceutical companies stealing as much basic research data they can from academic scientists, falsifying whatever they aren't able to steal, and publishing it all as their own independent research.
Believe it or not, there is still no system in place (though Mother Nature knows I tried -- through the NIH, NSF, FDA, UC Regents, the scientific journal where Agouron's half-stolen/half-falsified work was published, even the National Academies of Science -- until finally resorting to a legal remedy) for preventing pharmaceutical companies from behaving this way with non-patentable basic research work published in the scientific literature. And contrary to the faulty premise of this book (that scientific publications are of little value to anybody but academic scientists), such publications, even if presenting only basic research and nothing patentable yet, can be extremely valuable and sought after, especially to a budding start-up company, because they can add scientific prestige and even a big stock boost with the proper media attention.
The reason the beginning and end of this book stand out apart from the rest, as another reviewer notes, is because these are the parts that were probably written mostly by Agouron attorneys, as is evident from the fact that most of the writing in these parts seems to be just a regurgitation of seven years' worth of Karl Rove type press releases that Agouron issued against me during the course of this lawsuit, many of them hinting that I was not a very good scientist and that my main motivation in the lawsuit was just a sour grapes attempt to get money and attention:
"Without a major publication under her belt, Pelletier was simply a vulnerable and mostly unknown postdoctoral researcher, with little academic credit to invest in her own defense" (pg. 195). "As a young post-doctoral researcher, the (scientific project involved in the lawsuit) was supposed to be Dr. Pelletier's ticket to scientific success" (Introduction).
It is not like Ms. McSherry was unaware of my 1992 Ph.D. thesis from UCSD, which was unrelated to the work involved in the lawsuit and was completed two years before I finally sued Agouron in 1994 (after months of attempted negotiations with them to be reasonable and not publish the work they stole from me), two years before I became an apparently "unknown postdoctoral researcher with little academic credit and no major publication to her name."
For the record (which you are not going to get an accurate account of in this book), my Ph.D. thesis was published as a major research article in the top scientific journal in the country -- Science, soon thereafter became the second most cited paper in chemistry for its time period, was featured as a cover story for Chemical and Engineering News in February of 1993, landed several invited lectures for me around the world, including France, Germany, Italy, and China, and is to this day still featured in all major biochemistry textbooks.
Yes, Corynne McSherry was fully aware of my scientific accomplishments at the writing of this book, as was the unfortunately jealous subset from my laboratory whom she hung out with and who, at the behest of Agouron Pharmaceuticals, plotted and eventually succeeded at stealing my subsequent postdoctoral research work in 1992/1993 and handing it over to Agouron Pharmaceuticals for immediate publication.
"Who Owns Academic Work" was published, not-so-coincidentally, in the Fall of 2000, just weeks before an unprecedented and completely unfounded decision was handed down from a California Appeals Court on my case, where a well-deserved $200,000 monetary award against Agouron Pharmaceuticals that was granted to me by 12 out of 12 jurors after a two-week trial, was reduced to $1.00 despite every other aspect and decisions of the jurors being upheld. Why? Because, the Court ruled, they were not sure "who owns academic work." Apparently, the academic work that Agouron scientists stole from an academic laboratory and published as their own was, in effect, really owned by the public anyway, right? -- i.e. Agouron -- and the Court, against the better judgment of twelve of my peers, could find no damage done to me nor to my career that justified such a monetary award.
In other words, a young and talented academic female scientist's non-patentable basic research work is easy pickings and can be taken at will prior to publication by any pharmaceutical company and published as its own, as they saw fit, and heaven forfend that the young scientist have any recourse for this base and inexcusable action, lest the entire academic world suffer "earth-shattering consequences," as McSherry laughingly calls it.
In fact, if you read between the lines carefully enough (from both the book and the Court decision and even the reviews of the book), you could almost swear any such well-deserved decision against any US pharmaceutical company might pose a threat to national security! LOL!
Give me a break...
Help other customers find the most helpful reviews
Was this review helpful to you? Yes
No